Correlation of Primary Breast Cancer Histopathology and Estrogen Receptor Content

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1981 Jan 1

PMID 7348564

Citations 17

Authors

E R Fisher

C K Osborne

W L McGuire

C Redmond

W A Knight 3rd

B Fisher

G Bannayan

A Walder

E J Gregory

A Jacobsen

D M QUEEN

D E Bennett

H C FORD

Affiliations

Soon will be listed here.

Abstract

We studied the association of estrogen receptor (ER) with several histologic variables that correlate with breast tumor differentiation and with patient prognosis. Contingency table analysis revealed highly statistically significant correlations between ER content and histologic and nuclear grades, tumor necrosis, and the degree of elastosis and lymphoid cell infiltration. ER positive tumors were more likely than ER negative tumors to demonstrate histological evidence of tumor differentiation. All tumors with histologic grade 1 or nuclear grade 1 (best differentiated) were ER positive or borderline positive. Eighty-nine percent of ER negative tumors were histologic grade 3 and 78.4% were nuclear grade 3 (poor differentiation). ER positive tumors were also correlated with absent tumor necrosis, higher elastic content, and absent lymphoid cell infiltration, all features of good differentiation. Medullary carcinomas were frequently (73%) ER negative, but no relationship between ER and other morphologic types of breast cancer or 9 other morphologic variables was found. ER appears to be a biochemical marker for the degree of differentiation of human breast cancer providing a rationale for the observed differences in biological behavior between receptor positive and negative tumors.

Citing Articles

Relationship of Tubule Formation, Indian File Pattern and Apocrine Change With Estrogen and Progesterone Receptors and HER2 Immunostaining.

Singh D, Agarwal A, Anthony M, Paul P, Singh M, Rao S Cureus. 2022; 14(10):e30204.

PMID: 36381921 PMC: 9650915. DOI: 10.7759/cureus.30204.

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.

Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien A, Melisko M Nat Commun. 2020; 11(1):3584.

PMID: 32681091 PMC: 7367885. DOI: 10.1038/s41467-020-17414-y.

MultiDCoX: Multi-factor analysis of differential co-expression.

Liany H, Rajapakse J, Karuturi R BMC Bioinformatics. 2018; 18(Suppl 16):576.

PMID: 29297310 PMC: 5751780. DOI: 10.1186/s12859-017-1963-7.

Long-Term Cause-Specific Mortality After Surgery for Women With Breast Cancer: A 20-Year Follow-Up Study From Surveillance, Epidemiology, and End Results Cancer Registries.

Escarela G, Jimenez-Balandra A, Nunez-Antonio G, Gordillo-Moscoso A Breast Cancer (Auckl). 2017; 11:1178223417711429.

PMID: 28615951 PMC: 5459512. DOI: 10.1177/1178223417711429.

Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors.

Gupta D, Gupta V, Marwah N, Gill M, Gupta S, Gupta G Iran J Pathol. 2015; 10(1):23-34.

PMID: 26516322 PMC: 4539786.

References

Rich M, Furmanski P, Brooks S . Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res. 1978; 38(11 Pt 2):4296-8. View

Fisher E, Gregorio R, Redmond C, Dekker A, Fisher B . Pathologic findings from the national surgical adjuvant breast project (protocol no. 4). II. The significance of regional node histology other than sinus histiocytosis in invasive mammary cancer. Am J Clin Pathol. 1976; 65(1):21-30. DOI: 10.1093/ajcp/65.1.21. View

Meyer J, Rao B, Stevens S, White W . Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer. 1977; 40(5):2290-8. DOI: 10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t. View

WALT A, Singhakowinta A, Brooks S, Cortez A . The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery. 1976; 80(4):506-12. View

Fisher E, Gregorio R, Fisher B, Redmond C, VELLIOS F, SOMMERS S . The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975; 36(1):1-85. DOI: 10.1002/1097-0142(197507)36:1<1::aid-cncr2820360102>3.0.co;2-4. View

Bishop H, Blamey R, Elston C, Haybittle J, Nicholson R, Griffiths K . Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979; 2(8137):283-4. DOI: 10.1016/s0140-6736(79)90295-2. View

Fisher E, Redmond C, Liu H, Rockette H, Fisher B . Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer. 1980; 45(2):349-53. DOI: 10.1002/1097-0142(19800115)45:2<349::aid-cncr2820450226>3.0.co;2-p. View

Osborne C, Knight 3rd W, Yochmowitz M, McGuire W . Modern approaches to the treatment of breast cancer. Blood. 1980; 56(5):745-52. View

Silverstrini R, Daidone M, Di Fronzo G . Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer. 1979; 44(2):665-70. DOI: 10.1002/1097-0142(197908)44:2<665::aid-cncr2820440237>3.0.co;2-n. View

10.

Fisher E, Redmond C, Fisher B . Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure. Cancer. 1980; 46(4 Suppl):908-18. DOI: 10.1002/1097-0142(19800815)46:4+<908::aid-cncr2820461310>3.0.co;2-5. View

11.

McGuire W, de la Garza M, Chamness G . Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res. 1977; 37(3):637-9. View

12.

Meyer J, BAUER W, Rao B . Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. Lab Invest. 1978; 39(3):225-35. View

13.

Cooke T, George D, Shields R, Maynard P, Griffiths K . Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979; 1(8124):995-7. DOI: 10.1016/s0140-6736(79)92752-1. View

14.

Fisher E, Palekar A, Gregorio R, Redmond C, Fisher B . Pathological findings from the national surgical adjuvant breast project (Protocol No. 4). IV. Significance of tumor necrosis. Hum Pathol. 1978; 9(5):523-30. DOI: 10.1016/s0046-8177(78)80133-6. View

15.

Maynard P, Blamey R, Elston C, Haybittle J, Griffiths K . Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978; 38(11 Pt 2):4292-5. View

16.

KNIGHT W, Livingston R, Gregory E, McGuire W . Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977; 37(12):4669-71. View

17.

Hahnel R, Woodings T, VIVIAN A . Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979; 44(2):671-5. DOI: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. View

18.

Fisher E, Gregorio R, Redmond C, Kim W, Fisher B . Pathologic findings from the national surgical adjuvant breast project. (Protocol no. 4). III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol. 1976; 65(4):439-44. DOI: 10.1093/ajcp/65.4.439. View